Neurologic Outcomes and Postresuscitation Care of Patients With Myoclonus Following Cardiac Arrest*

David B. Seder, MD1; Kjetil Sunde, MD, PhD2; Sten Rubertsson, MD3; Michael Mooney, MD2; Pascal Stammet, MD4; Richard R. Riker, MD1; Karl B. Kern, MD5; Barbara Unger, RN6; Tobias Cronberg, MD7; John Dziodzio, BA1; Niklas Nielsen, MD, PhD7,8; for the International Cardiac Arrest Registry

Objectives: To evaluate the outcomes of cardiac arrest survivors with myoclonus receiving modern postresuscitation care.

Design: Retrospective review of registry data.

Setting: Cardiac arrest receiving centers in Europe and the United States from 2002 to 2012.

Patients: Two thousand five hundred thirty-two cardiac arrest survivors 18 years or older enrolled in the International Cardiac Arrest Registry.

Interventions: None.

Measurements and Main Results: Eighty-eight percent of patients underwent therapeutic hypothermia and 471 (18%) exhibited myoclonus. Patients with myoclonus had longer time to professional cardiopulmonary resuscitation (8.6 vs 7.0 min; \(p < 0.001\)) and total ischemic time (25.6 vs 22.3 min; \(p < 0.001\)) and less often presented with ventricular tachycardia/ventricular fibrillation, a witnessed arrest, or had bystander cardiopulmonary resuscitation. Electroencephalography demonstrated myoclonus with epileptiform activity in 209 of 374 (55%), including status epilepticus in 102 of 374 (27%). Good outcome (Cerebral Performance Category 1–2) at hospital discharge was noted in 9% of patients with myoclonus, less frequently in myoclonus with epileptiform activity (2% vs 15%; \(p < 0.001\)). Patients with myoclonus with good outcome were younger (53.7 vs 62.7 yr; \(p < 0.001\)), had more ventricular tachycardia/ventricular fibrillation (81% vs 46%; \(p < 0.001\)), shorter ischemic time (18.9 vs 26.4 min; \(p = 0.003\)), more witnessed arrests (91% vs 77%; \(p = 0.02\)), and fewer “do-not-resuscitate” orders (7% vs 78%; \(p < 0.001\)). Life support was withdrawn in 330 of 427 patients (78%) with myoclonus and poor outcome, due to neurological futility in 293 of 330 (89%), at 5 days (3–8 d) after resuscitation. With myoclonus and good outcome, median ICU length of stay was 8 days (5–11 d) and hospital length of stay was 14.5 days (9–22 d).

Conclusions: Nine percent of cardiac arrest survivors with myoclonus after cardiac arrest had good functional outcomes, usually in patients without associated epileptiform activity and after prolonged hospitalization. Deaths occurred early and primarily after withdrawal of life support. It is uncertain whether prolonged care would yield a higher percentage of good outcomes, but myoclonus of itself should not be considered a sign of futility. (Crit Care Med 2015; 43:965–972)

Key Words: arrest; cardiac; myoclonic; myoclonus; seizure; status epilepticus

Myoclonus, described as brief, involuntary twitching of a muscle or a group of muscles, is a common manifestation of neurological injury after cardiac arrest, and its clinical meaning, prevalence, and treatment are much debated. Pathophysiologically correlates to myoclonus after cardiac arrest include cortical injury, injury to deep white matter tracts, and injury to the deep gray matter structures (1). Animal research shows that injury to the ventrolateral...
thalamus is associated with clinical myoclonus (2, 3), and functional imaging of patients that survive cardiac arrest with late myoclonus shows increased fludeoxyglucose uptake in the same area (4). The prevalence of such injuries may depend on the duration of circulatory arrest (no-flow interval), duration and severity of hypoperfusion (low-flow interval), relative contribution of hypoxemia, presence or absence of focal cerebrovascular stenosis, microvascular disease, the severity of reperfusion injury after restoration of blood flow, and other factors. Biochemically, myoclonus after cardiac arrest is associated with decreased spinal fluid serotonin, and in rat models, serotonin replacement ameliorates myoclonus (5–7). Some authors have suggested that “subcortical” myoclonus may differ from “cortical myoclonus” (8–10), and recent work confirmed that myoclonus after cardiac arrest may originate from either cortical or subcortical injury (11), yet this nomenclature has not been validated with physiologic or autopsy studies, and remains problematic.

Generalized myoclonus after circulatory arrest is often called “status myoclonus,” characterized by coma, sustained (> 30 min) bilateral muscle twitching, and predominantly poor outcomes (12–17). Although cortical electroencephalography (EEG) discharges are frequently seen in status myoclonus, simultaneous electrical discharges have not been required in most descriptions to make the diagnosis (1, 6, 15, 16), and it is unclear if status myoclonus with epileptiform discharges has a different prognosis than status myoclonus without EEG correlates (6, 11, 14, 18–21). By contrast, the so-called Lance-Adams Syndrome is described as an intention or action myoclonus, occurring later, typically in awake patients after cardiac arrest or severe hypoxia, and associated with better functional outcomes (2, 6, 22, 23). A histopathological comparison of these entities has not been undertaken, and distinguishing the clinical entities can be difficult. Unanticipated recovery of patients exhibiting early myoclonus after resuscitation is the subject of multiple case reports but occurs rarely (15, 24–28). This unexpected recovery is of concern, since most inpatient deaths after cardiac arrest are due to withdrawal of life support (29, 30), and confusion about the classification of postcardiac arrest myoclonus might contribute to incorrect prognostication and unnecessary deaths.

In 1985, prior to the routine utilization of targeted temperature management (TTM), Levy et al (16) reported 90% poor neurological outcomes in patients with myoclonus after cardiac arrest. Two widely cited articles followed, describing no survivors in large case series among patients with status myoclonus (12, 13), referred to as an “agonal” phenomenon (12). These articles were a basis for 2006 Guidelines issued by the American Academy of Neurology, which offered a strong opinion of futility when status myoclonus was present after an arrest (31). We now attempt to characterize the prevalence, neuromonitoring practices, outcomes, and mode and timing of death among patients with myoclonus after cardiac arrest in a large registry population, most of whom received TTM. We also describe the patient characteristics and hospital course of survivors, in an effort to give clinicians a sense of the time frame for awakening, suggesting how long it might be reasonable to wait for recovery of neurologic function.

**MATERIALS AND METHODS**

This observational, registry-based study of cardiac arrest survivors was conducted in the International Cardiac Arrest Registry (INTCAR). INTCAR is a secure, web-based database involving 34 sites in Europe and the United States. The core INTCAR dataset is composed of 87 de-identified data points with standardized definitions, focusing on elements of post–cardiac arrest care. Research approval is obtained locally, and sites must maintain institutional review board approval for data collection and participation. INTCAR approved this registry-based project, and data analyses were performed at Maine Medical Center. See Appendix 1 for participating sites.

**Patients**

Two thousand five hundred and thirty-two patients included unconscious (Glasgow Coma Scale motor score < 6), adult (≥18 yr old) patients admitted to the ICU after in- or out-of-hospital cardiac arrest. The study period was 2002–2012. Centers were asked to register all patients consecutively, and each treated patients according to its own therapeutic protocols, cardiac care pathways, and temperature management equipment.

**Dataset**

Data collection regarding patient characteristics, comorbidities, cardiac arrest–related factors, and time points followed the Utstein recommendations (32–34). Cardiac arrest data were recorded from ambulance and emergency medical services records, using standardized definitions. The database provided automatic range checks, and all entries were manually reviewed for plausibility and logic. Site investigators were contacted to clarify data when appropriate. On-site monitoring was not performed.

Data related to intensive care management and adverse events were recorded according to a predefined protocol. The use of electroencephalogram, including limited or continuous recordings, was identified, and dominant EEG background patterns, epileptiform activity including periodic discharges, electrographic seizures, and electrographic status epilepticus were recorded. Abnormal movements, including convulsions and myoclonus, were also recorded. We further assessed the utilization of TTM and other treatments, all adverse events, utilization of “do-not-resuscitate” orders, and the withdrawal of life support.

Patients with myoclonus who were also reported to have periodic epileptiform discharges, seizures, or status epilepticus on EEG were considered to have “myoclonus with epileptiform activity,” whereas those with EEG monitoring who had no epileptiform activity were classified as having “myoclonus without epileptiform activity.” Many patients with myoclonus did not undergo EEG, and so this distinction could not be made for all patients. Timing, persistence, and location of the myoclonus is not reported, so status myoclonus could not be distinguished from occasional myoclonic jerks or a late action myoclonus.
Outcome Measurement
The primary outcome was neurological function at hospital discharge, assessed in terms of Cerebral Performance Category (CPC): CPC 1 indicates no or minor neurologic disability, able to work; CPC 2 indicates moderate neurologic disability, able to work in a sheltered environment; CPC 3 indicates severe neurologic disability, dependent on others for daily activities; CPC 4 indicates coma or vegetative state; and CPC 5 indicates dead. Classifications of CPC 1 or 2 were regarded as good neurologic outcomes.

Statistical Analysis
Proportions are expressed as percentages. Continuous data are expressed as mean and so or as medians with interquartile ranges where nonnormal distributions were identified. Differences of proportions were assessed using a chi-square test. Continuous variables were compared using Student t test or Mann-Whitney-Wilcoxon rank-sum test as appropriate. Categorical variables were compared using a chi-square test. Two-tailed tests of significance were used, and p value less than or equal to 0.05 was considered significant.

RESULTS
Of 2,532 patients in the Registry, 471 (19%) were observed to have myoclonus (Fig. 1). Table 1 compares characteristics of cardiac arrest survivors with myoclonus with those without, whereas Table 2 compares the characteristics of patients with myoclonus and good functional outcome with those with myoclonus and poor functional outcome.

Thirty-nine percent of patients in the total cohort and 374 of 471 patients with myoclonus (79%) underwent some kind of EEG monitoring—either intermittent or continuous (Table 3). Of these, 194 underwent continuous EEG, and 180 had only intermittent EEG. Among patients with myoclonus who underwent EEG monitoring, 209 of 374 (55%) had epileptiform activity, meeting criteria for “myoclonus with epileptiform activity.” Of these, 102 of 374 (27%) had electrographic status epilepticus.

Forty-four patients with myoclonus (9%) were described as CPC 1 or CPC 2 (good outcome) at hospital discharge (Table 4). EEG was performed in 31 of 44 patients with myoclonus and good outcome, and “myoclonus without epileptiform activity” was reported in 26 of 31 (84%) while five patients (Table 5) had “myoclonus with epileptiform activity,” including two with electrographic status epilepticus. Among the 374 patients with EEG monitoring and myoclonus, CPC of 1 or 2 was reported in five of 205 patients (2%) with “myoclonus with epileptiform activity” and 26 of 170 patients (15%) with “myoclonus without epileptiform activity” (p < 0.001). Table 6 describes EEG findings and outcomes of the overall registry population.

DISCUSSION
This is the first article to describe the prevalence, EEG findings, and outcomes of patients with myoclonus after cardiac arrest in a large, multicenter registry cohort largely treated with TTM. The prevalence of myoclonus (18%) was lower than described in the pre-TTM era (16) and similar to two recent series treated with hypothermia (11, 35). Myoclonus was associated with many factors related to brain injury severity, including longer total ischemic time, a nonshockable initial heart rhythm, unwitnessed arrest, and lack of bystander cardiopulmonary resuscitation (CPR). Yet, the magnitude of these differences was not profound. Patients with “myoclonus without epileptiform activity” had better outcomes than those with “myoclonus with epileptiform activity,” yet even when epileptiform activity was present, a small number, including two with electrographic status epilepticus, did well. Twenty-one percent of patients with myoclonus after cardiac arrest did not undergo EEG monitoring, which limits the completeness of our analysis, but also speaks to many clinicians’ point of view that when myoclonus is present after cardiac arrest, EEG is not required to interpret its significance. Although most patients with myoclonus had poor outcomes, 89% of these died due to withdrawal of life support at a median of only 5 days postresuscitation and at 3 days or less in 25%. Conversely, patients with myoclonus with good outcome had a median ICU stay of 8 days and 14.5 days of hospitalization, raising the question of whether life support might have prematurely been withdrawn in some of those that died early.

This is also the first study to report a significant distinction in outcomes between cardiac arrest survivors with myoclonus and the presence or absence of associated epileptiform activity on EEG. Our findings differ from studies performed in the pre-TTM era in which the prevalence of myoclonus was described as 30–40% (14, 16). In our cohort, the prevalence of myoclonus was 19%, which agrees with a recent single-center Dutch experience (11), and is slightly lower than the 23–28% rate seen in the TTM Trial (35). Although it is impossible to know if the patients in these cohorts were similar, one possible explanation for the decreased prevalence of myoclonus compared to historical cohorts is less severe brain injury due to the utilization...
of TTM, modern ICU care, higher rates of bystander CPR, and shorter no-flow intervals. This registry cohort included 57% of patients with an initial heart rhythm of ventricular tachycardia or ventricular fibrillation, which is higher than most epidemiological samples of cardiac arrest survivors—therefore, the patients in our registry may represent a less severely injured cohort than that seen in many centers, where rates of myoclonus may be higher than 19%. Another explanation is that the severity of brain injury is unchanged, but routine utilization of neuromuscular blockade and/or sedation to control shivering in patients undergoing TTM masks myoclonic activity (36).

Several recent reports have called for delayed prognostication and increased conservatism in outcome prediction after cardiac arrest (37–39). The longer duration of care in our cohort of patients with myoclonus with good outcomes raises the question of whether prolonged supportive measures might have led to more good outcomes. We conjecture that the negative implications of status myoclonus (12, 31) may have driven early discontinuation of life support in some patients that would have made a good functional recovery. This series shows with certainty that status myoclonus patients who have good outcomes required prolonged ICU care and a longer hospital course than

### TABLE 1. Demographics and Clinical Characteristics of Cardiac Arrest Survivors Comparing Those With or Without Myoclonus

<table>
<thead>
<tr>
<th>Demographics and Clinical Factors</th>
<th>All Patients (n = 2,532)</th>
<th>Patients Without Myoclonus (n = 2,061)</th>
<th>Patients With Myoclonus (n = 471)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean, sd)</td>
<td>62.3 ± 15.3</td>
<td>62.4 ± 15.2</td>
<td>61.8 ± 15.9</td>
<td>0.43</td>
</tr>
<tr>
<td>Female (n, %)</td>
<td>771/2,527 (31)</td>
<td>634/2,057 (31)</td>
<td>137/470 (29)</td>
<td>0.48</td>
</tr>
<tr>
<td>Rhythm ventricular tachycardia/ventricular fibrillation (n, %)</td>
<td>1,388/2,395 (58)</td>
<td>1,164/1,944 (60)</td>
<td>224/451 (50)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Witnessed (n, %)</td>
<td>2,112/2,518 (84)</td>
<td>1,752/2,048 (86)</td>
<td>360/470 (77)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Bystander cardiopulmonary resuscitation (n, %)</td>
<td>1,505/2,434 (62)</td>
<td>1,245/1,974 (63)</td>
<td>260/460 (57)</td>
<td>0.009</td>
</tr>
<tr>
<td>No-flow time (mean, sd)</td>
<td>7.29 ± 7.12</td>
<td>6.99 ± 7.06</td>
<td>8.60 ± 7.23</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Total ischemic time (mean, sd)</td>
<td>23.0 ± 17.4</td>
<td>22.3 ± 17.7</td>
<td>25.6 ± 15.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>In-hospital arrest (n, %)</td>
<td>643/2,531 (25)</td>
<td>567/2,060 (27)</td>
<td>76/471 (16)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Admission Glasgow Coma Scale motor subscore (median, interquartile range)</td>
<td>1 (1–3)</td>
<td>1 (1–3)</td>
<td>1 (1–1)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

### TABLE 2. Demographics and Clinical Characteristics of Cardiac Arrest Survivors With Myoclonus, Comparing Those With Myoclonus and Good Versus Poor Neurologic Outcome at Hospital Discharge

<table>
<thead>
<tr>
<th>Demographics and Clinical Factors</th>
<th>All Patients With Myoclonus (n = 471)</th>
<th>Patients With Myoclonus and Poor Outcome (n = 427)</th>
<th>Patients With Myoclonus and Good Outcome (n = 44)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean, sd)</td>
<td>61.8 ± 15.9</td>
<td>62.7 ± 15.7</td>
<td>53.7 ± 15.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Female (n, %)</td>
<td>137/470 (29)</td>
<td>124/426 (29)</td>
<td>13/44 (30)</td>
<td>0.95</td>
</tr>
<tr>
<td>Rhythm ventricular tachycardia/ventricular fibrillation (n, %)</td>
<td>224/451 (50)</td>
<td>190/409 (47)</td>
<td>34/42 (81)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Witnessed (n, %)</td>
<td>360/470 (77)</td>
<td>360/426 (75)</td>
<td>40/44 (91)</td>
<td>0.02</td>
</tr>
<tr>
<td>Bystander cardiopulmonary resuscitation (n, %)</td>
<td>260/460 (57)</td>
<td>234/419 (56)</td>
<td>26/41 (63)</td>
<td>0.35</td>
</tr>
<tr>
<td>No-flow time (mean, sd)</td>
<td>8.60 ± 7.23</td>
<td>8.76 ± 7.33</td>
<td>7.07 ± 6.13</td>
<td>0.15</td>
</tr>
<tr>
<td>Total ischemic time (mean, sd)</td>
<td>25.6 ± 15.5</td>
<td>26.4 ± 15.6</td>
<td>18.9 ± 12.7</td>
<td>0.003</td>
</tr>
<tr>
<td>In-hospital arrest (n, %)</td>
<td>76/471 (16)</td>
<td>68/427 (16)</td>
<td>8/44 (18)</td>
<td>0.70</td>
</tr>
<tr>
<td>Admission Glasgow Coma Scale motor subscore (median, interquartile range)</td>
<td>1 (1–1)</td>
<td>1 (1–1)</td>
<td>1 (1–1.5)</td>
<td>0.003</td>
</tr>
<tr>
<td>Hypothermia therapy (n, %)</td>
<td>444/471 (94.3)</td>
<td>402/427 (94.1)</td>
<td>42/44 (95.5)</td>
<td>1</td>
</tr>
<tr>
<td>Neuromuscular blockade (n, %)</td>
<td>276/374 (73.8)</td>
<td>247/343 (72.0)</td>
<td>29/31 (93.5)</td>
<td>0.016</td>
</tr>
</tbody>
</table>
other survivors. Waiting the “minimum” time for awakening and recovery in patients with myoclonus prior to discontinuation of life support is likely to result in lost opportunities for good outcome. It also highlights the need for multimodal prognostication after cardiac arrest (37, 40, 41), including measures such as somatosensory-evoked potentials and serum or imaging biomarkers.

Only 79% of patients with myoclonus after cardiac arrest underwent any (intermittent or continuous) EEG monitoring. This may relate to either inconsistent use or availability of EEG monitoring, or perhaps to the unclear definition of status myoclonus, which does not require EEG (6, 15). Because status myoclonus has previously been described as early and severe myoclonus, some centers make no attempt to determine whether this is an epileptic or nonepileptic phenomenon.

Myoclonus after cardiac arrest may coincide with cortical epileptiform discharges, which we see are associated with markedly different outcomes; we believe that EEG in such patients

| Table 3. Electroencephalographic Findings of Cardiac Arrest Survivors With Myoclonus |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|------------------|
| **Epileptiform Activity and Anticonvulsants** | **All Patients With Myoclonus (n = 471) (%)** | **Myoclonus and Poor Outcome (n = 427) (%)** | **Myoclonus and Good Outcome (n = 44) (%)** | **p** |
| Any electroencephalography | 374/471 (79) | 343/417 (82) | 31/44 (71) | 0.06 |
| Severe background attenuation | 75/374 (20) | 73/343 (21) | 2/31 (6) | 0.08 |
| Burst suppression | 153/374 (41) | 149/343 (43) | 4/31 (13) | 0.002 |
| Continuous background | 91/374 (24) | 74/343 (22) | 17/31 (55) | <0.001 |
| Nonreactive background | 41/374 (11) | 41/343 (12) | 0/31 (0) | 0.08 |
| Any epileptiform activity | 205/374 (55) | 200/343 (58) | 5/31 (16) | <0.001 |
| Periodic epileptiform discharges | 104/374 (28) | 101/343 (29) | 3/31 (10) | 0.03 |
| Electrographic seizures | 56/374 (15) | 55/343 (16) | 1/31 (3) | 0.09 |
| Electrographic status epilepticus | 102/374 (27) | 100/343 (29) | 2/31 (6) | 0.01 |
| Anticonvulsants | 301/369 (82) | 276/338 (82) | 25/31 (81) | 0.9 |

| Table 4. Outcomes of Cardiac Arrest Survivors With Myoclonus |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|------------------|
| **Directives and Outcomes** | **All Patients With Myoclonus (n = 471)** | **Patients With Myoclonus and Poor Outcome (n = 427)** | **Patients With Myoclonus and Good Outcome (n = 44)** | **p** |
| Do-not-resuscitate order (n, %) | 335/470 (71) | 332/426 (78) | 3/44 (7) | <0.001 |
| Withdrawal support-futility (n, %) | 293/471 (62) | 293/427 (69) | 0 | <0.001 |
| ICU LOS (median, IQR) | 5 (3–8) | 5 (3–8) | 8 (5–11) | <0.001 |
| Hospital LOS (median, IQR) | 11 (7–19) | 9 (6–17) | 14.5 (9–22) | 0.01 |

LOS = length of stay, IQR = interquartile range.

| Table 5. Characteristics of Cardiac Arrest Survivors With Myoclonus and Epileptiform Activity That Survived With a Good Outcome |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|------------------|
| **Age, Gender** | **Total Ischemic Time** | **Epileptiform Activity** | **Targeted Temperature Management Dosing** | **Antiepileptic Drugs** | **ICU LOS** | **Hospital LOS** | **Best ICU CPC** | **Discharge CPC** |
| 80, Male | 30 | PEDs, status epilepticus | 33°C × 24 hr | Yes | 8 | 60 | 4 | 2 |
| 41, Male | 22 | PEDs | 33°C × 24 hr | Yes | 15 | 72 | 3 | 2 |
| 54, Female | Unknown | Seizures | 33°C × 24 hr | Yes | 6 | 19 | 3 | 2 |
| 48, Male | 7 | PEDs | 33°C × 24 hr | Yes | 12 | 13 | 1 | 1 |
| 42, Female | 35 | Status epilepticus | 33°C × 24 hr | Yes | 18 | 23 | 2 | 1 |

LOS = length of stay, CPC = Cerebral Performance Category, PEDs = periodic epileptiform discharges.

This may relate to either inconsistent use or availability of EEG monitoring, or perhaps to the unclear definition of status myoclonus, which does not require EEG (6, 15). Because status myoclonus has previously been described as early and severe myoclonus, some centers make no attempt to determine whether this is an epileptic or nonepileptic phenomenon. Myoclonus after cardiac arrest may coincide with cortical epileptiform discharges, which we see are associated with markedly different outcomes; we believe that EEG in such patients...
is important and useful. It may be used to identify the underlying EEG background rhythm, detect and guide the treatment of seizures, gather prognostic information, and help define the regions and severity of brain injury. Determining the precise electrophysiological and imaging correlates of status myoclonus may help distinguish a cortical pattern of injury from deeper injury involving basal ganglia or brain stem. Such patterns of injury are being studied using neuroimaging and neurophysiological techniques (17, 42, 43), but a careful prospective study correlating the neuroimaging patterns of brain injury to EEG findings, clinical myoclonus, and outcomes with aggressive treatment has not been performed. Such research is critically needed to better describe variations in the brain injuries incurred during and after cardiac arrest, their clinical correlates, and their prognostic significance.

This study has several weaknesses and limitations. Like all retrospective research, it depends on accurate data entry and consistent interpretations of clinical scenarios by data collectors. Although INTCAR uses standardized definitions for data entry, complex data points may still be differently interpreted. This especially pertains to EEG interpretation, which may suffer from high interobserver variability even among like-minded practitioners (44). Specifically, not using a standardized template and complex definitions for EEG interpretation, such as the American Clinical Neurophysiology Society’s Standardized Critical Care EEG Terminology (45), or detailed definitions of what constitutes a convulsion are important weaknesses of these data. Furthermore, like all registries, there are missing data points of interest, such as the presence of absence of brainstem reflexes at the time of hospital or ICU admission, which is an important early indicator of brain injury severity (17, 46). Second, we are not able to distinguish between status myoclonus (which may be a sign of poor prognosis) and myoclonic jerks (which are not). Third, patients treated with continuous neuromuscular blockade may not have manifestations of myoclonus. Untreated myoclonus after cardiac arrest is rarely subtle, however, often manifesting most dramatically after the rewarming period, when neuromuscular blockade is not used, so we think this was unlikely to confound our results significantly. The strength of the study includes the size and comprehensive nature of our data, spanning Europe and the United States, with generalizable conclusions describing real-world practices and trends.

**CONCLUSIONS**

Nine percent of cardiac arrest survivors treated with TTM and exhibiting the physical examination finding of myoclonus after cardiac arrest had good functional outcomes. When the myoclonus was not associated with epileptiform activity on EEG, 15% had a good outcome. Death with myoclonus often occurred early and primarily after withdrawal of life support, but it is uncertain whether prolonged care would yield a higher percentage of good outcomes. EEG should be performed in patients with myoclonus after cardiac arrest, and the physical examination finding of myoclonus of itself should not be interpreted as a sign of futility. High-quality prospective studies that clarify the pathophysiology of myoclonus after cardiac arrest, aggressively support patients, and reliably identify patients with survivable injuries are urgently needed.

**ACKNOWLEDGMENTS**

We thank the patients and their families as well as our dedicated data abstractors for their support of this project. We thank the Scandinavian Society of Anesthesia and Intensive Care and the Stig and Ragna Gorthon Foundations for their financial support of the International Cardiac Arrest Registry version 1.0.

**REFERENCES**

2. Fahn S: Posthypoxic action myoclonus: Review of the literature and report of two new cases with response to valproate and estrogen. Adv Neurol 1979; 26:49–84

5. Kanthasamy AG, Nguyen BO, Truong DD: Animal model of posthy-

5. pxic myoclonus: II. Neurochemical, pathologic, and pharmacologic
6. Venkatesan A, Frucht S: Movement disorders after resuscitation from

7. Goetz CG, Vu TQ, Carvey PM, et al: Posthypoxic myoclonus in the

7. rat: Natural history, stability, and serotonergic influences. *Mov Disord*
8. Hallett M: Physiology of human posthypoxic myoclonus. *Mov Disord*
1998; 38:401–405


13. Venkatesan A, Frucht S: Movement disorders after resuscitation from

13. cardiac arrest: The Utstein Style. A statement for health professionals
from a task force of the American Heart Association, the European
Resuscitation Council, the Heart and Stroke Foundation of Canada,
Symposium: Recommended guidelines for reviewing, reporting, and
conducting research on post-resuscitation care: The Utstein style.
timing and adverse events in therapeutic hypothermia after out-of-hospital
Targeted temperature management at 33°C versus 36°C after car-

17. Thömke F, Weilemann SL: Poor prognosis despite successful

17. treatment of postanoxic generalized myoclonus. *Neurology* 2010;
74:1392–1394
18. Cronberg T, Brizzi M, Liedholm LJ, et al; Neurological prognosti-
cation after cardiac arrest—Recommendations from the Swedish
post resuscitation hypothermia: Are we pulling the plug too early?
*Resuscitation* 2014; 85:211–214
20. Tsai MS, Chen JY, Chen WJ, et al: Do we need to wait longer for car-
diac arrest survivor to wake up in hypothermia era? *Am J Emerg Med*
2013; 31:888.e5–888.e6
after cardiac arrest and therapeutic hypothermia. *Crit Care* 2014;
18:202
22. Friberg H, Rundgren M, Westhall E, et al: Continuous evaluation of
neurological prognosis after cardiac arrest. *Acta Anaesthesiol Scand*
2013; 57:6–15
23. Greer DM, Rosenthal ES, Wu O: Neuroprognostication of hypoxic-
ischaeamic coma in the therapeutic hypothermia era. *Nat Rev Neurol*
2014; 10:190–203
profile of brain diffusion-weighted MRI after cardiac arrest. *Stroke*
2010; 41:1665–1672
ment in the interpretation of EEG patterns in critically ill adults. *J Clin
Neurophysiol* 2008; 25:241–249
Neurophysiology Society’s Standardized Critical Care EEG
severity score to predict outcome after cardiac arrest. *Resuscitation*
2011; 82:1399–1404
APPENDIX 1. Participating Sites and Their Patient Contributions

1. Landspitali University Hospital—Reykjavik, Iceland (120)
2. Asklepios Kliniken—Langen, Germany (23)
3. Östersund Hospital—Ostersund, Sweden (20)
4. Örebro, University Hospital—Örebro Municipality, Sweden (22)
5. Skåne University Hospital—Lunds Universitet, Lund, Sweden (111)
6. Kungälv Hospital—Kungälv, Sweden (18)
7. Kristianstad Central Hospital—Kristianstad, Sweden (33)
8. Blekingesjukhuset—Karlskrona, Sweden (37)
9. Karlstad Central Hospital—Karlstad, Sweden (18)
10. Kalmar hospital—Kalmar, Sweden (11)
11. Evangelisches Krankenhhaus—Wien, Austria (11)
12. Halmstad Regional Hospital—Halmstad, Sweden (31)
13. Falu hospital—Falun, Sweden (29)
14. Danderyd Hospital—Danderyd, Sweden (20)
15. Uppsala University Hospital—Uppsala, Sweden (166)
16. Ulleval University Hospital—Ulleval University Hospital, Oslo, Norway (204)
17. Stavanger University Hospital—Stavanger, Norway (102)
18. Centre Hospitalier de Luxembourg—Luxembourg, Luxembourg (89)
19. Rigshospitalets Heart Center—Copenhagen, Denmark (61)
20. Gentofte Hospital—Gentofte Hospital, Hellerup, Denmark (25)
21. Cardiocenter, General Teaching Hospital—Prague, Czech Republic (151)
22. St. John’s Mercy Medical Center—St. Louis, MO (110)
23. Ochsner Baptist Medical Center—New Orleans, LA (40)
24. Sarver Heart Center—University of Arizona, Tucson, AZ (36)
25. Vanderbilt University Medical Center—Nashville, TN (188)
26. Lehigh Valley Health Network—Allentown, PA (171)
27. Minneapolis Heart Institute—Minneapolis, MN (276)
28. Central Maine Medical Center—Lewiston, ME (11)
29. Eastern Maine Medical Center—Bangor, ME (119)
30. Maine Medical Center—Tufts University, Portland, ME (226)
31. Kärnsjukhuset, Sweden (13)
32. Sjukhuset i Lidköping—Lidköping, Sweden (10)
33. Columbia University, New York, NY (13)
34. Swedish Medical Center, Englewood, CO (24)